EA200702253A1 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция

Info

Publication number
EA200702253A1
EA200702253A1 EA200702253A EA200702253A EA200702253A1 EA 200702253 A1 EA200702253 A1 EA 200702253A1 EA 200702253 A EA200702253 A EA 200702253A EA 200702253 A EA200702253 A EA 200702253A EA 200702253 A1 EA200702253 A1 EA 200702253A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
quinazolinamines
treatment
methods
well
Prior art date
Application number
EA200702253A
Other languages
English (en)
Russian (ru)
Inventor
Барри Говард Картер
Дуэйн А. Кэмпбелл
Original Assignee
Смитклайн Бичем
Корк] Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200702253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичем, Корк] Лимитед filed Critical Смитклайн Бичем
Publication of EA200702253A1 publication Critical patent/EA200702253A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200702253A 2005-04-19 2006-04-18 Фармацевтическая композиция EA200702253A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19
PCT/US2006/014447 WO2006113649A1 (en) 2005-04-19 2006-04-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
EA200702253A1 true EA200702253A1 (ru) 2008-04-28

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702253A EA200702253A1 (ru) 2005-04-19 2006-04-18 Фармацевтическая композиция

Country Status (28)

Country Link
US (3) US8821927B2 (enExample)
EP (1) EP1871347B1 (enExample)
JP (1) JP5202302B2 (enExample)
KR (1) KR101356748B1 (enExample)
CN (1) CN101203211B (enExample)
AR (1) AR054252A1 (enExample)
AU (1) AU2006236423B2 (enExample)
BR (1) BRPI0609962B1 (enExample)
CA (1) CA2606207C (enExample)
CY (1) CY1118179T1 (enExample)
DK (1) DK1871347T3 (enExample)
EA (1) EA200702253A1 (enExample)
ES (1) ES2601503T3 (enExample)
HR (1) HRP20161429T1 (enExample)
HU (1) HUE030982T2 (enExample)
IL (1) IL186336A0 (enExample)
LT (1) LT1871347T (enExample)
MA (1) MA29404B1 (enExample)
MX (1) MX2007013089A (enExample)
NO (1) NO20075111L (enExample)
NZ (1) NZ562223A (enExample)
PE (1) PE20061430A1 (enExample)
PL (1) PL1871347T3 (enExample)
PT (1) PT1871347T (enExample)
SI (1) SI1871347T1 (enExample)
TW (1) TW200716204A (enExample)
WO (1) WO2006113649A1 (enExample)
ZA (1) ZA200708705B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821927B2 (en) * 2005-04-19 2014-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical composition
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
WO2011039759A1 (en) * 2009-09-29 2011-04-07 Natco Pharma Limited A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
ES2530755T3 (es) 2010-05-21 2015-03-05 Glaxosmithkline Llc Terapia de combinación para el tratamiento del cáncer
EA030145B1 (ru) 2010-08-03 2018-06-29 Велисепт Терапьютикс, Инк. Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2014128107A1 (en) 2013-02-19 2014-08-28 Hexal Ag Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EA201791225A1 (ru) 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
KR100520401B1 (ko) 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
JP4102185B2 (ja) 2000-06-30 2008-06-18 グラクソ グループ リミテッド キナゾリンジトシル酸塩化合物
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
WO2003086467A1 (en) 2002-04-08 2003-10-23 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
EP1810034A4 (en) * 2002-06-19 2008-06-25 Smithkline Beecham Corp PREDICTIVE MARKERS IN CANCER THERAPY
US8821927B2 (en) * 2005-04-19 2014-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical composition

Also Published As

Publication number Publication date
EP1871347A1 (en) 2008-01-02
CN101203211B (zh) 2012-08-08
CA2606207A1 (en) 2006-10-26
HRP20161429T1 (hr) 2016-12-16
MX2007013089A (es) 2008-01-14
CA2606207C (en) 2014-11-18
AU2006236423B2 (en) 2009-12-10
NO20075111L (no) 2007-11-16
JP5202302B2 (ja) 2013-06-05
ES2601503T3 (es) 2017-02-15
PT1871347T (pt) 2016-11-10
EP1871347B1 (en) 2016-08-03
PL1871347T3 (pl) 2017-04-28
AR054252A1 (es) 2007-06-13
US20140335177A1 (en) 2014-11-13
IL186336A0 (en) 2008-01-20
DK1871347T3 (en) 2016-11-28
PE20061430A1 (es) 2007-01-25
TW200716204A (en) 2007-05-01
MA29404B1 (fr) 2008-04-01
US20080206330A1 (en) 2008-08-28
ZA200708705B (en) 2009-12-30
JP2008536931A (ja) 2008-09-11
KR20080005557A (ko) 2008-01-14
EP1871347A4 (en) 2012-10-31
BRPI0609962B1 (pt) 2022-01-18
US8821927B2 (en) 2014-09-02
SI1871347T1 (sl) 2016-11-30
WO2006113649A1 (en) 2006-10-26
AU2006236423A1 (en) 2006-10-26
HUE030982T2 (en) 2017-06-28
KR101356748B1 (ko) 2014-02-06
BRPI0609962A2 (pt) 2011-10-11
NZ562223A (en) 2010-01-29
LT1871347T (lt) 2016-11-10
US20160143909A1 (en) 2016-05-26
CN101203211A (zh) 2008-06-18
CY1118179T1 (el) 2017-06-28

Similar Documents

Publication Publication Date Title
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
NO20075111L (no) Farmasoytisk sammensetning
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY30500A1 (es) Compuestos de azabencimidazolilo
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
GB0625648D0 (en) Compounds
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TW200637817A (en) 5-aminoindole derivatives
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.